KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Current Deferred Revenue (2019 - 2025)

Historic Current Deferred Revenue for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to $30.7 million.

  • Esperion Therapeutics' Current Deferred Revenue rose 10346.86% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year increase of 10346.86%. This contributed to the annual value of $8.5 million for FY2024, which is 6646.72% down from last year.
  • Per Esperion Therapeutics' latest filing, its Current Deferred Revenue stood at $30.7 million for Q3 2025, which was up 10346.86% from $22.3 million recorded in Q2 2025.
  • Esperion Therapeutics' 5-year Current Deferred Revenue high stood at $30.7 million for Q3 2025, and its period low was $2.5 million during Q1 2021.
  • Moreover, its 5-year median value for Current Deferred Revenue was $8.5 million (2024), whereas its average is $12.4 million.
  • In the last 5 years, Esperion Therapeutics' Current Deferred Revenue surged by 62432.28% in 2023 and then crashed by 8452.47% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Current Deferred Revenue (Quarter) stood at $5.7 million in 2021, then plummeted by 38.29% to $3.5 million in 2022, then skyrocketed by 624.32% to $25.4 million in 2023, then plummeted by 66.47% to $8.5 million in 2024, then soared by 260.17% to $30.7 million in 2025.
  • Its Current Deferred Revenue stands at $30.7 million for Q3 2025, versus $22.3 million for Q2 2025 and $4.5 million for Q1 2025.